Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 27,094 | 23,927 | 26,477 | 20,493 | — |
| Current assets | 7,778 | 7,608 | 10,874 | 6,536 | — |
| Cash and equivalents | 1,017 | 1,690 | 5,919 | 1,497 | — |
| Short-term investments | 714 | 1,115 | 594 | 745 | — |
| Inventory | 1,472 | 1,117 | 1,013 | 1,041 | — |
| Net property, plant and equipment | 11,797 | 10,623 | 9,905 | 8,286 | — |
| Goodwill | 3,586 | 2,761 | 2,781 | 2,688 | — |
| Other intangible assets | 1,197 | 791 | 789 | 803 | — |
| Long-term investments | 640 | 649 | 723 | 630 | — |
| Current liabilities | 8,364 | 4,224 | 3,654 | 3,912 | — |
| Accounts payable | 607 | 477 | 412 | 406 | — |
| Long-term debt | 1,772 | 4,377 | 8,200 | 4,454 | — |
| Total debt | 7,040 | 5,975 | 9,698 | 6,117 | — |
| Total liabilities | 11,355 | 9,705 | 13,239 | 9,653 | — |
| Total equity (incl. minority) | 15,739 | 14,223 | 13,238 | 10,840 | — |
| Retained earnings | 7,679 | 6,443 | 5,205 | 4,152 | — |
| Minority interest | 674 | 604 | 681 | 291 | — |